Investor Presentation

70 Investor presentation First six months of 2022 Novo NordiskⓇ Global phase 3a trial investigating oral semaglutide 50 mg in obesity initiated in Q3 2021 and expected to complete in H1 2023 Global trial planned was started in H2 2021 Plan to include 660 patients with obesity Oral semaglutide 50 mg R 1:1 Placebo oral Objective To investigate superiority of oral semaglutide 50 mg vs. placebo on weight loss in people with overweight or obesity Primary endpoint Change in body weight from baseline (%) • Body weight reduction ≥ 5% 68 weeks 7 weeks follow-up OASIS programme scope Inclusion criteria • BMI: ≥27 kg/m² with ≥ 1 weight-related comorbidity, or • BMI ≥30 kg/m² • Weight-related comorbidities are hypertension, dyslipidaemia, obstructive sleep apnoea and CVD OASIS: Oral Semaglutide treatment effect In people with Obesity; CVD: Cardiovascular disease; BMI: Body Mass Index Total of 1,000 patients across three trials: 1) A global (North America and Europe), 2) Japanese and 3) Chinese trial

View entire presentation